Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer
The purpose of this study is to find out if the combination of gemcitabine and oxaliplatin chemotherapy will be effective in reducing or eliminating the tumor(s) in patients with recurrent or metastatic breast cancer.
Gemcitabine is a chemotherapy drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic and lung cancer; oxaliplatin is a chemotherapy drug that is approved by the FDA for the treatment of colon cancer. Neither gemcitabine nor oxaliplatin are approved for the treatment of breast cancer. However, both drugs have been shown to decrease the size of breast cancer tumors.
|Recurrent Breast Cancer Metastastic Breast Cancer||Drug: Gemcitabine and oxaliplatin||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00159458
|United States, California|
|Norris Comprehensive Cancer Center|
|Los Angeles, California, United States, 90033|
|Santa Monica, California, United States, 90404|
|Principal Investigator:||Christy Russell, MD||LAC+USC Medical Center|